<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2011</study_start_year><condition>Major Advanced Solid Tumors Other Than Colorectal</condition><disease>Major Advanced Solid Tumors Other Than Colorectal</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2110616</full_dataset_link><location>United States</location><study_start_month>11</study_start_month><keyword>Pharma Mar</keyword><keyword>Non-Colorectal Cancer (non-CRC)</keyword><keyword>PM01183</keyword><keyword>Dose finding phase I</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks</name><description>Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.</description><dates><creation>2011-11-15</creation></dates><accession>2110616</accession><cross_references><ClinicalTrials___gov>NCT01405391</ClinicalTrials___gov></cross_references></HashMap>